


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PASSING OF CONSISTENCY EVALUATION FOR
“PARECOXIB SODIUM FOR INJECTION”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Parecoxib Sodium for Injection” (brand name: Yu An (予安)) (specifications: 20mg and 40mg), an analgesic of the Group, has obtained the notice of approval of supplemental applications issued by the National Medical Products Administration of the People’s Republic of China, and has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs (the “**Consistency Evaluation**”).

Parecoxib Sodium for Injection is the only injectable selective cyclooxygenase-2 (COX-2) inhibitor at home and abroad. It is mainly used for the treatment of postoperative pain and is one of the basic drugs for clinical multimodal analgesia. Parecoxib sodium is a highly selective COX-2 inhibitor with good analgesic effect, rapid onset, long-lasting effect, high gastrointestinal safety, no effect on platelet function, and no additional cardiovascular risk. Combined with opioids, it can significantly reduce the dose of opioids and related adverse reactions.

Parecoxib Sodium for Injection has been recommended by domestic and foreign authoritative guidelines to be widely applied in the treatment of postoperative pain in many departments such as general surgery, gynecology, orthopedics, and stomatology. Having passed the Consistency Evaluation, the two specifications of Yu An will help further promote import substitution and allow more patients to benefit from high-quality domestic drugs.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 January 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.